Streetbeat News

Revenues

JAGGF

Jaguar Mining Inc. announced its production results for Q4 and full year 2024, with full financial results to be reported by March 27, 2025.

Portfolio Pulse from

January 13, 2025 | 11:45 am

SWTX

SpringWorks Therapeutics announced its preliminary financial results for Q4 and full year 2024 at the J.P. Morgan Healthcare Conference. The company reported $61.5 million in Q4 and $172.0 million in full year U.S. net product revenues for OGSIVEO (nirogacestat).

Portfolio Pulse from

January 13, 2025 | 11:45 am

AKA

a.k.a. Brands Holding Corp. reported a 6.8% increase in net sales for Q4 2024, with U.S. sales rising by 21.6%.

Portfolio Pulse from

January 13, 2025 | 11:45 am

REGN

Regeneron Pharmaceuticals provided updates at the J.P. Morgan Healthcare Conference, highlighting the growth of Dupixent, EYLEA, and Libtayo, as well as advancements in their clinical pipeline. EYLEA HD's pre-filled syringe is set for a mid-2025 launch, and Linvoseltamab's BLA has been resubmitted. The company also announced a collaboration with Truveta to enhance its healthcare database.

Portfolio Pulse from

January 13, 2025 | 11:45 am

BAMXF

BMW reported a decline in annual sales due to weak demand in China and Germany, aligning with trends seen by other German automakers.

Portfolio Pulse from

January 13, 2025 | 11:30 am

TRIN

Trinity Capital is highlighted as a strong BDC due to its diversified asset mix, floating-rate exposure, and consistent dividend coverage. It offers a 14% yield with potential for a 2% dividend hike in 2Q25. The company's net investment income increased by 26% YoY in 3Q24, driven by new originations and higher interest rates.

Portfolio Pulse from

January 13, 2025 | 11:30 am

EWCZ

European Wax Center, Inc. has provided an update ahead of the 2025 ICR Conference, reporting on fiscal 2024 net new center openings and updating its fiscal 2024 financial outlook.

Portfolio Pulse from

January 13, 2025 | 11:15 am

SIRI

Sirius XM Holdings stock has dropped by 60% this year due to challenges in the automotive industry and advertising trends. Despite this, the stock is considered undervalued with a fair estimate of $27 per share, 25% above the current market price.

Portfolio Pulse from

January 13, 2025 | 11:15 am

PTGX

Protagonist Therapeutics is anticipating significant developments in 2025, including results from the phase 3 VERIFY study for rusfertide in treating polycythemia vera and positive outcomes from ICONIC studies using JNJ-2113 for plaque psoriasis. The global market for polycythemia vera is projected to grow significantly by 2032.

Portfolio Pulse from

January 13, 2025 | 11:15 am

AHH

Armada Hoffler has completed a full-floor office lease with Trader Interactive at the Town Center of Virginia Beach, highlighting significant office activity in the mixed-use district.

Portfolio Pulse from

January 13, 2025 | 11:15 am